Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Assess and address
How can patient perceptions of asthma control affect disease management?
Improving asthma control has a direct impact on the quality of life of patients, helping them return to doing the things they love to do.
When measured using the Asthma Quality of Life Questionnaire (AQLQ), 27% more patients improved their quality of life vs other commonly used ICS/LABAs in everyday practice.*1
AQLQ responders at 12 months (%)*
Usual care was ICS or ICS/LABA. ICS monotherapy in the usual care group included beclomethasone, budesonide, ciclesonide and fluticasone. ICS/LABAs in the usual care group included beclomethasone/formoterol, budesonide/formoterol, fluticasone/formoterol and fluticasone/salmeterol.2
This graph has been independently created by GSK from the original data. The same results were first published in Svedsater H, et al. Respir Med 2018;141:198–206.
This graph has been independently created by GSK from the original data. The same results were first published in Svedsater H, et al. Respir Med 2018;141:198–206.
The Asthma Quality of Life Questionnaire (AQLQ) is clinically validated to assess the physical and emotional impact of asthma3
Questions are answered on a scale of 1–7, where 7=not impaired, 1=severely impaired. Results are expressed as an average score for each of the four domains and as an overall average.
Symptom-free nights
According to GINA, one of the key indicators of poor asthma control is experiencing night-time symptoms.4 For many patients, this parameter may also impact their quality of life.
In an analysis of three studies, Relvar significantly increased the percentage of symptom-free nights vs placebo and FF (OR: 2.89 [95% CI 1.74–4.80] and 1.74 [1.10–2.74]) in one study, and was associated with a numerically higher percentage of symptom-free nights vs FF and FP in the other two studies.5
This graph has been independently created by GSK from the original data. The same results were first published in Kerwin E, et al. J Asthma 2018;55:890–897.
This graph has been independently created by GSK from the original data. The same results were first published in Kerwin E, et al. J Asthma 2018;55:890–897.
This graph has been independently created by GSK from the original data. The same results were first published in Kerwin E, et al. J Asthma 2018;55:890–897.
The long-lasting effects of Relvar
How long do these effects last, and what is it about Relvar molecules that leads to such improvements in the first place?
Discover Relvar
21st-century molecules[6–9]
Relvar’s unique combination of fluticasone furoate, a potent inhaled corticosteroid, and vilanterol, an ultra-long-β2-agonist, delivers the everyday stability asthma patients need.1,6,7,10–16
Footnotes
*Quality of life was measured by the Asthma Quality of Life Questionnaire at 12 months. A clinically meaningful improvement was defined as an increase from baseline of ≥0.5 units. Data presented are from a subset of patients in the ITT population prescribed ICS/LABA at baseline who were initiated with Relvar or continued on their existing ICS/LABA.1
†Analysis of the environmental stimuli domain was pre-planned.1
‡Data from a post-hoc analysis.
Abbreviations
AE, adverse event; AQLQ, Asthma Quality of Life Questionnaire; CI, confidence interval; FF, fluticasone furoate; FP, fluticasone propionate; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; ITT, intention-to-treat; LABA, long-acting β2-agonist; OD, once daily; OR, odds ratio; VI, vilanterol.
Relvar Safety Information18
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Undesirable effects
Very Common: Headache, Nasopharyngitis.
Common: Infections and infestations, Oropharyngeal pain, Sinusitis, Pharyngitis, Rhinitis, Cough, Dysphonia, Abdominal pain, Arthralgia, Back pain, Fractures, Muscle spasms and Pyrexia.
References
- Svedsater H, et al. Respir Med 2018;141:198–206.
- GSK Data on File 219213; 2023.
- Juniper EF, et al. J Clin Epidemiol 1994;47:81–87.
- GINA. Global strategy for asthma management and prevention, 2023. Available at: www.ginasthma.org. Accessed April 2024.
- Kerwin E, et al. J Asthma 2018;55:890–897.
- Bernstein DI, et al. J Asthma 2015;52:1073–1083.
- Global Datasheet Fluticasone furoate/vilanterol: v13, September 2022.
- Braithwaite I, et al. Respir Med 2016;119:115–121.
- Center for Drug Evaluation and Research. Approval package for Breo Ellipta. Application number: 204275Orig1s000. Accessed April 2024.
- Woodcock A, et al. Lancet 2017;390:2247–2255.
- Averell CM, et al. J Asthma 2022;59:1805–1818.
- Daley-Yates P, et al. Adv Ther 2023;40:4042–4059.
- Parimi M, et al. Adv Ther 2020;37:2916–2931.
- van der Palen J, et al. NPJ Prim Care Respir Med 2016;26:16079.
- van der Palen J, et al. Respir Med 2022;205:107031.
- Janson C, et al. Thorax 2020;75:82–84.
- Woodcock A, et al. Thorax 2022;77:1187–1192.
- Relvar Prescribing Information.
GSK does not recommend, endorse, or accept liability for the 3rd party sites.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني https://moh.gov.om/en/ : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies
PM-RCH-FFV-WCNT-250001 Date of preparation: July 2025
